IsoRay Releases Significant Results for Cesium-131 Isotope and Ebay's PayPal Embarking on New Marketing Efforts

IsoRay, Inc. (NYSE: ISR) announced the publication of the first major peer reviewed study showing improved results using the company’s Cesium-131 seeds in the treatment of gynecologic cancer. Company CEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds chosen for use in the treatment of gynecologic cancers. We believe our marketing is most successful by teaming up with medical industry thought leaders as they seek better solutions and outcomes for their patients. As we continue to develop our product offerings internally with support from industry leaders,